US Patent Issued to MedImmune on May 19 for "GLP-1 and glucagon dual agonist peptides with improved biological stability" (British Inventors)

ALEXANDRIA, Va., May 19 -- United States Patent no. 12,630,600, issued on May 19, was assigned to MedImmune Ltd. (Cambridge, Great Britain).

"GLP-1 and glucagon dual agonist peptides with improved biological stability" was invented by Sivaneswary Genapathy (Cambridge, Great Britain) and Maria Aleksandra Bednarek (Cambridge, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "GLP-1 and glucagon dual agonists disclosed herein have improved biological stability, including proteolytic stability, and duration of action. The peptides can be administered about once a week."

The patent was filed on Feb. 6, 2023, under Application No. 18/164,802.

*For further information, including images, charts and table...